Phase Ib/IIa Trial to Evaluate Oregovomab and Nivolumab in Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin

NCT03100006 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

13

Enrollment

OTHER

Sponsor class

Stopped The study had poor efficacy.

Conditions

Epithelial Ovarian Cancer

Interventions

DRUG: Nivolumab
DRUG: Oregovomab

Sponsor

National Cancer Centre, Singapore